November 20, 2026 · American heart journal · DOI: 10.1016/j.ahj.2026.107660

Culprit vessel TIMI 0-1 flow identifies a high-risk subgroup of NSTEMI patients with multivessel disease: a post-hoc analysis of the SLIM randomized clinical trial.

Listen to this summary

This post-hoc analysis of the SLIM randomized trial asks whether culprit-vessel TIMI 0-1 flow, a surrogate for occlusive myocardial infarction, identifies a high-risk subgroup among NSTEMI patients with multivessel disease. In 474 patients, TIMI 0-1 flow was not detectable on admission ECG interpretation, was more common in younger male patients with a circumflex culprit, and was independently associated with higher 1-year MACE after adjustment (aHR 2.09, p=0.026), though unadjusted rates did not differ significantly (p=0.061).

Arpad Árpád Lux, Matteo Betti, Tobias F S Pustjens, Roberto Bova, Samuel Heuts, Arnoud W J van 't Hof, Saman Rasoul

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play